A growing body of research suggests that when cancer treatment is given may be just as important as what treatment is given. A recent study has found that administering immunochemotherapy at specific times of the day significantly improves survival outcomes in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer worldwide.
NSCLC accounts for nearly 85% of all lung cancer cases. Treatment often involves a combination of chemotherapy and immunotherapy—known as immunochemotherapy—which works by both directly attacking cancer cells and stimulating the body’s immune system to recognise and destroy them. While advances in these therapies have already improved survival rates, researchers are now exploring how the body’s internal clock, or circadian rhythm, may influence treatment effectiveness.
.png)